Effects of an anti-platelet drug (dilazep) in IgA nephropathy: comparison of clinical effects with renal biopsy findings.
To investigate renal biopsy findings arising in response to treatment with an anti-platelet drug in IgA nephropathy, 46 patients were treated with dilazep dihydrochloride (Dilazep), and a retrospective comparison was performed between the clinical effects and renal biopsy findings. After 6 months of treatment, 18 patients (39%) were judged to be improved if their proteinuria was ameliorated by a 25% or greater decrease with improved or persistent renal function. The group of improved patients exhibited mean decreased levels of urinary proteins in the range from 1.9 to 0.8 g/day after treatment (p < 0.01). By contrast, the unimproved group showed increased urinary proteins in the range from 1.2 to 2.0 g/day (p < 0.05). The improved group showed histological findings with fewer glomeruli exhibiting sclerosis and/or cellular crescents, with a lesser increase in mesangial matrix and with smaller tubulo-interstitial lesions than the unimproved group. By immunofluorescence, the improved group was found to have smaller amounts of glomerular IgA and IgG deposits. These findings suggest that an anti-proteinuric effect of Dilazep administration can be expected in patients with IgA nephropathy with relatively mild glomerulo-sclerotic lesions.
Yoshida
H
H
Department of Pathology, Kyoto University Hospital, Japan.
Kanatsu
K
K
Muso
E
E
Kuwahara
T
T
Sekita
K
K
Ono
T
T
Konishi
N
N
Kanda
C
C
Minakata
T
T
Morimoto
K
K
D000328:Adult; D001706:Biopsy; D004109:Dilazep / Q000627:therapeutic use*; D005260:Female; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D007668:Kidney / Q000473:pathology*; D008297:Male; D011507:Proteinuria / Q000188:drug therapy; D012189:Retrospective Studies
D007136:Immunoglobulins; D004109:Dilazep